Rudakova I G, Kotov A S, Kotov S V, Belova Iu A, Lavrent'eva N S
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(10):25-9.
One hundred and thirty-eight patients (76 women and 62 men, aged from 16 to 65 years) with symptomatic partial epilepsy (n=128) and idiopathic generalized epilepsy (n=10) have been studied. All patients received keppra on regiments of monotherapy (n=30) and polytherapy (n=108). The study included evaluation of anamnesis, clinical and neurophysiological examination, routine EEG and/or video-EEG-monitoring, MRI of the brain, assessment of effectiveness, tolerability and quality of life (QUALIE-31, version 1). The period of observation was 1-4 years (on average 2,5 years). The high effectiveness and tolerability, good characteristics of therapy duration, the early appearance of clinical effect after the therapy has been started and positive cognitive effect are noted. The effectiveness, tolerance and clinical features of keppra treatment in different epileptic syndromes are analyzed.
对138例患者(76例女性和62例男性,年龄在16至65岁之间)进行了研究,其中有症状性部分性癫痫患者128例,特发性全身性癫痫患者10例。所有患者均接受左乙拉西坦单药治疗(n = 30)和联合治疗(n = 108)。该研究包括对病史、临床和神经生理学检查、常规脑电图和/或视频脑电图监测、脑部磁共振成像、疗效评估、耐受性评估以及生活质量评估(QUALIE - 31,第1版)。观察期为1至4年(平均2.5年)。研究发现左乙拉西坦具有高效性和耐受性,治疗持续时间特征良好,治疗开始后临床效果出现早,且具有积极的认知效果。分析了左乙拉西坦治疗不同癫痫综合征的疗效、耐受性和临床特征。